Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Green Cross Corporation (006280:KRX), powered by AI.
Green Cross Corporation is currently trading at ₩131,100. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Green Cross Corporation on Alpha Lenz.
Green Cross Corporation's P/E ratio is -327.8.
“Green Cross Corporation trades at a P/E of -327.8 (undervalued) with modest ROE of -0.4%.”
Ask for details →Green Cross Corporation is a prominent pharmaceutical company based in South Korea, primarily focused on developing and manufacturing therapeutic biologics and vaccines. With a strong emphasis on biotechnology, the company produces a wide array of products including blood derivatives, vaccines for various infectious diseases, and plasma-based therapies. Green Cross Corporation plays a pivotal role in the healthcare industry, both domestically and internationally, by contributing to public health initiatives and vaccine distribution efforts. As a leader in the biotechnology sector, the company is committed to research and development, driving innovations that enhance treatment options and improve patient outcomes. In the financial market, Green Cross Corporation holds significance as a key player in the pharmaceutical industry, influencing health-focused investment strategies and offering insights into biotechnological advancements. Founded with the mission of improving health and extending life, Green Cross continues to strengthen its market presence through strategic partnerships and a robust pipeline of new products, positioning itself as a critical contributor to global healthcare solutions.
“Green Cross Corporation trades at a P/E of -327.8 (undervalued) with modest ROE of -0.4%.”
Ask for details →Green Cross Corporation (ticker: 006280) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 2,009 employees. Market cap is $1.5T.
The current price is ₩131,100 with a P/E ratio of -327.8x and P/B of 1.26x.
ROE is -0.38% and operating margin is 3.47%. Annual revenue is $2.0T.